SCHEDULE 13G: Nantahala Capital Management Discloses 8.43% Stake in Avalo Therapeutics

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 8.43% in Avalo Therapeutics, Inc. as of March 31, 2025.

Summary

• Nantahala Capital Management, LLC, an investment adviser, along with its managing members Wilmot B. Harkey and Daniel Mack, have filed a Schedule 13G.
• The filing indicates beneficial ownership of 900,000 shares of Avalo Therapeutics, Inc. Common Stock.
• This aggregate amount represents 8.43% of the total outstanding shares of Avalo Therapeutics, Inc.
• The reporting persons hold shared voting and shared dispositive power over all 900,000 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or outlook. It simply reports a significant stake.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing indicates a significant passive investment by an investment adviser in Avalo Therapeutics, a company operating in the biotechnology sector. Such disclosures are common and reflect investment firms taking positions in publicly traded companies, which can signal confidence or strategic interest in the sector or specific company.

Stakeholder Impact

• Shareholders: The disclosure of a significant ownership stake by an investment firm may be viewed positively by existing shareholders as it indicates institutional interest and potential confidence in the company's value. It also provides transparency regarding major holders.

Key Dates

Keywords

Avalo Therapeutics, Nantahala Capital Management, Wilmot B. Harkey, Daniel Mack, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment Adviser, Biotechnology, Pharmaceuticals